The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 16, 2013
Filed:
Nov. 13, 2006
John J. Baldwin, Gwynedd Valley, PA (US);
David A. Claremon, Maple Glen, PA (US);
Colin Tice, Ambler, PA (US);
Salvacion Cacatian, Blue Bell, PA (US);
Lawrence W. Dillard, Yardley, PA (US);
Alexey V. Ishchenko, Somerville, PA (US);
Jing Yuan, Lansdale, PA (US);
Zhenrong Xu, Horsham, PA (US);
Gerard Mcgeehan, Garnet Valley, PA (US);
Robert D. Simpson, Wilmington, DE (US);
Suresh B. Singh, Kendall Park, NJ (US);
Wei Zhao, Eagleville, PA (US);
Patrick T. Flaherty, Pittsburgh, PA (US);
John J. Baldwin, Gwynedd Valley, PA (US);
David A. Claremon, Maple Glen, PA (US);
Colin Tice, Ambler, PA (US);
Salvacion Cacatian, Blue Bell, PA (US);
Lawrence W. Dillard, Yardley, PA (US);
Alexey V. Ishchenko, Somerville, PA (US);
Jing Yuan, Lansdale, PA (US);
Zhenrong Xu, Horsham, PA (US);
Gerard McGeehan, Garnet Valley, PA (US);
Robert D. Simpson, Wilmington, DE (US);
Suresh B. Singh, Kendall Park, NJ (US);
Wei Zhao, Eagleville, PA (US);
Patrick T. Flaherty, Pittsburgh, PA (US);
Vitae Pharmaceuticals, Inc., Fort Washington, PA (US);
Abstract
The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.